Skip to content
Screener

Dianthus Therapeutics DNTH Other Costs — Research And Development Expense

Other product segments

Personnel And Related Costs
$8.64M+47.7%
Share Based Compensation Expense
$4.85M
Discovery Expenses
$1.36M+51.4%

Similar metrics at other companies

Rapport Therapeutics, Inc. logo
RAPPOther Costs — Research And Development Expense
$1.82M+13.2%
Disc Medicine logo
IRONOther Research — Research And Development Expense
$2.17M+18.2%
Solid Biosciences Inc. logo
SLDBInternal Research And Development Expense — Research And Development Expense
$9.06M+33.9%
Disc Medicine logo
IRONInternal Research And Development — Research And Development Expense
$11.31M+67.6%
Rein Therapeutics Inc. logo
RNTXFacilities And Other Expenses — Research And Development Expense
$25K+56.3%
Beam Therapeutics logo
BEAMExternal Research And Development Expenses — Research And Development Expense
$30.08M-12.6%

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$6.15B+838%
Enterprise value$5.52B+758%

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0.0×
Current ratio29.3×+13.3×

Where this comes from

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:06 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001690585-26-000022
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Discovery expenses1,363900
Personnel and related costs8,6355,847
Stock-based compensation expense4,8482,475
Other costs1,4931,190
Total research and development expenses34,52827,003
General and administrative expenses:
Stock-based compensation expense5,7542,840
Personnel and related costs4,0612,561

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Dianthus Therapeutics's other costs — research and development expense?
Dianthus Therapeutics (DNTH) reported other costs — research and development expense of $1.49M in Q1 2026.
How has Dianthus Therapeutics's other costs — research and development expense changed year-over-year?
Dianthus Therapeutics's other costs — research and development expense increased by 25.5% year-over-year, from $1.19M to $1.49M.
What does other costs — research and development expense mean?
This metric represents the aggregate costs incurred by the company for early-stage research activities and exploratory development projects that are not directly attributable to a specific lead clinical program. It captures the foundational investment in scientific discovery and platform technology development necessary to build a sustainable pipeline. Monitoring this expense helps investors assess the company's commitment to long-term innovation and the scalability of its underlying research engine.

Ask your AI about Dianthus Therapeutics's other costs — research and development expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude